Eversheds Sutherland has advised Peptonic
June 26, 2024
Eversheds Sutherland has advised PeptonicJune 26, 2024 Eversheds Sutherland advised Peptonic Medical AB ("Peptonic") on its SEK 61.4 million rights issue of units. Peptonic is a biomedical company engaged in the research and development of pharmaceuticals and medical devices in the field of women's health. The company's vision is to provide treatments for women's health and medical conditions. The company develops hormone-free products for the treatment of vaginal atrophy and vaginal dryness. The company has its headquarters in Sweden. Eversheds Sutherland’s team consisted of Mark Falkner, John Edgren and Hanna Ullerholt. Mangold Fondkommission AB acted as financial advisor to Peptonic. Latest NewsLatest Events
virtual UAE - Employment law in the Dubai International Financial Centre September 10, 2026 9.30am - 1.30pm (GMT) Virtual in-person September 10, 2026 9.30am - 1.00pm (BST) London, United Kingdom in-person September 17, 2026 9.30am - 4.30pm (GMT) London, United Kingdom in-person September 23, 2026 Washington DC, United States |